Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant

被引:7
作者
Ahmed, T
Rashid, K
Waheed, F
Kancherla, R
Qureshi, Z
Hoang, A
Richter, J
Ali, MF
Goldberg, R
Liu, D
Seiter, K
机构
[1] New York Med Coll, Dept Hematol Oncol, Valhalla, NY 10595 USA
[2] Zalmen A Arlin Canc Inst, Valhalla, NY USA
关键词
tandem transplant; refractory lymphoma; mitoxantrone;
D O I
10.1080/10428190400019826
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dose-intensive chemotherapy with autologous stem cell support is commonly used in resistant/refractory cases of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). The purpose of this study was to evaluate the role of tandem transplantation in these patients. We used non cross-resistant conditioning regimens with thiotepa, mitoxantrone and carboplatin (TMJ) followed by ifosphamide, carboplatin and etoposide ( ICE) with autologous stem cell rescue in an attempt to maximize dose intensity and achieve long-term remission. Seventy-six patients were included in this study. Twenty-nine patients with HD and 47 with NHL underwent autologous stem cell transplant using TMJ as the conditioning regimen for the first transplant. Of these, 49 patients proceeded to the second transplant using ICE as the conditioning regimen. In 57 patients, only peripheral blood cells were used and in 11 patients both bone marrow and peripheral stem cells were used. Twelve patients died due to treatment-related toxicity. On an intent to treat basis, 32.14% of patients with HD refractory to initial or subsequent therapy survived long term as opposed to 12.76% of patients with NHL. With a median follow-up of 83 months (range 25-110 months), the median disease-free survival of patients with HD was 7 months, as opposed to 2 months for patients with NHL. Multivariate analysis identified that patients with HD had a superior outcome if they were less than 35 years of age and did not have B symptoms. Dose-intensive chemotherapy with tandem transplantation is an option in patients with resistant/refractory lymphoma who have very limited treatment options and poor prognosis.
引用
收藏
页码:405 / 414
页数:10
相关论文
共 39 条
[1]   Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].
Aleman, BMP ;
Raemaekers, JMM ;
Tirelli, U ;
Bortolus, R ;
van't Veer, MB ;
Lybeert, MLM ;
Keuning, JJ ;
Carde, P ;
Girinsky, T ;
van der Maazen, RWM ;
Tomsic, R ;
Vovk, M ;
van Hoof, A ;
Demeestere, G ;
Lugtenburg, PJ ;
Thomas, J ;
Schroyens, W ;
De Boeck, K ;
Baars, JW ;
Kluin-Nelemans, JC ;
Carrie, C ;
Aoudjhane, M ;
Bron, D ;
Eghbali, H ;
Smit, WGJM ;
Meerwaldt, JH ;
Hagenbeek, A ;
Pinna, A ;
Henry-Amar, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406
[2]   Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].
Alyea, EP ;
Soiffer, RJ ;
Canning, C ;
Neuberg, D ;
Schlossman, R ;
Pickett, C ;
Collins, H ;
Wang, YL ;
Anderson, KC ;
Ritz, J .
BLOOD, 1998, 91 (10) :3671-3680
[3]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[4]   Single versus double autologous stem-cell transplantation for multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Facon, T ;
Guilhot, F ;
Doyen, C ;
Fuzibet, JG ;
Monconduit, M ;
Hulin, C ;
Caillot, D ;
Bouabdallah, R ;
Voillat, L ;
Sotto, JJ ;
Grosbois, B ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502
[5]   High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma [J].
Ballestrero, A ;
Clavio, M ;
Ferrando, F ;
Gonella, R ;
Garuti, A ;
Sessarego, M ;
Ghio, R ;
Gobbi, M ;
Patrone, F .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 17 (05) :1007-1013
[6]   Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Desikan, KR ;
Mattox, S ;
Vesole, D ;
Siegel, D ;
Tricot, G ;
Munshi, N ;
Fassas, A ;
Singhal, S ;
Mehta, J ;
Anaissie, E ;
Dhodapkar, D ;
Naucke, S ;
Cromer, J ;
Sawyer, J ;
Epstein, J ;
Spoon, D ;
Ayers, D ;
Cheson, B ;
Crowley, J .
BLOOD, 1999, 93 (01) :55-65
[7]   Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].
Bollard, CM ;
Rössig, C ;
Calonge, MJ ;
Huls, MH ;
Wagner, HJ ;
Massague, J ;
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
BLOOD, 2002, 99 (09) :3179-3187
[8]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[9]   Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD) [J].
Brice, P ;
Divine, M ;
Simon, D ;
Coiffier, B ;
Leblond, V ;
Simon, M ;
Voilat, L ;
Devidas, A ;
Morschhauser, F ;
Rohrlich, P ;
André, M ;
Lepage, E ;
Ferme, C .
ANNALS OF ONCOLOGY, 1999, 10 (12) :1485-1488
[10]   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].
Carella, AM ;
Cavaliere, M ;
Lerma, E ;
Ferrara, R ;
Tedeschi, L ;
Romanelli, A ;
Vinci, M ;
Pinotti, G ;
Lambelet, P ;
Loni, C ;
Verdiani, S ;
De Stefano, F ;
Valbonesi, M ;
Corsetti, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924